Markets

SELLAS Soars 156% on Leukemia Trial, Then Sells Stock

SELLAS Life Sciences jumped 156% to about $19 on November 17, 2026 after its Phase 3 REGAL leukemia vaccine trial met its overall survival goal.

A small biotech company more than doubled in a day on a single trial result, and by the evening it was asking investors for money. SELLAS Life Sciences said its Phase 3 REGAL trial of galinpepimut-S, a vaccine designed to train the immune system against leukaemia cells, met its primary goal of improving overall survival. The shares closed up 156.36% at about $19.02, after rising as much as 240% during the day, on a session when the S&P 500 fell 1.03%.

The trial tested the vaccine as maintenance treatment in patients with acute myeloid leukaemia who had reached a second or later remission but could not have a stem cell transplant, a group with few options. Median overall survival was 24.0 months with the vaccine against 14.7 months with the best available treatment. The hazard ratio was 0.59, meaning a 41% lower risk of death at any point during the study, with a two-sided p-value of 0.035, below the usual 0.05 threshold for statistical significance. The company said the treatment was generally well tolerated.

After the close SELLAS launched a $150 million underwritten stock offering with J.P. Morgan and TD Cowen, with an option for underwriters to buy $22.5 million more. The shares fell 10.57% in after-hours trading. Selling stock straight after good news is common in biotech: it lets a company raise money at a much higher price than a week earlier, but it also dilutes existing holders, and new shares usually come at a discount to the last trade.

Approval is still a step away. SELLAS plans to meet the US Food and Drug Administration to discuss an accelerated filing and is preparing a Biologics License Application for the first half of 2027. Secondary endpoints and other analyses are still being studied and will be presented at a medical conference. The analysis was triggered after 80 deaths, a modest number, and regulators will look at the full data, not only the headline survival figures.

The contrast with the day before is the useful part. On Monday Summit Therapeutics fell 16.47% after the FDA declined to approve its lung cancer drug, whose trial improved the time before the disease worsened but not survival. SELLAS showed the opposite: a survival benefit, the endpoint regulators value most. Both moves happened in a single session, with no chance to adjust a position in between, which is why trial readouts are among the hardest events in the market to trade.

By Trade2Spike Team, in-house editorial team. About us · Methodology